A pharmacological modality to sequester homomeric proteins
Ella Livnah, Ohad SussiD, Adi RogeliD, Atar GilatiD, Yuval Abdan, José A. VillegasiD, Ronen GabizoniD, Almog Nadir, Yoav Shamir, Noam Y. SteinmaniD, Barr Tivon, Shira AlbeckiD, Tamar UngeriD, Ofra GolaniiD, Inna GoliandiD, Nadav EladiD, Sílvia CarvalhoiD, Khriesto A. Shurrush, Haim Michael BarriD, David Margulies, Emmanuel D. LevyiD, Nir LondoniD
Abstract
Molecules that can perturb protein-protein interactions have an immense impact on chemical biology and therapeutics. However, such compounds typically rely on accessory proteins to function, such as E3 ligases in the case of targeted degradation, which may restrict their target and tissue scope or lead to resistance. Here we alleviate the need for accessory proteins with a novel pharmacological modality to knock-down protein function. Our strategy exploits protein symmetry as a selective vulnerability, and is widely applicable owing to the ubiquitous nature of homomeric proteins in cellular systems. We target homomeric proteins with PINCHs (Polymerization Inducing Chimeras) - bifunctional molecules composed of two linked ligands that act as bridges between homomers and trigger their supramolecular assembly into insoluble polymers. We design PINCHs that achieve efficient polymerization of three homomeric targets. In cells, we observed that a PINCH targeting Keap1 exhibited a longer duration of action compared to its monomeric inhibitor, and a PINCH targeting BCL6 displayed selective and improved B cell toxicity compared to its monomeric parent. Our results highlight PINCHs as a novel and general strategy to modulate and knock out protein function.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- FWCI
- 8.21
- Field percentile
- top 3%
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeted Kinase Degradation via the KLHDC2 Ubiquitin E3 Ligase
- Characterizing drug activity with sensitive interactomes in human living cells
Cindy Kundlacz, Nawal Hajj Sleiman, … Samir Merabet·bioRxiv·Nov 20, 2025
- Heterobifunctional Protein Binders Enable Cell Type-Specific Killing Through In-cell Enrichment
Ahmed Bulldan, Min Jing Zheng, … Felix Hausch·bioRxiv·May 16, 2025
- Targeted protein degradation via intramolecular bivalent glues
O. Hsia, M. Hinterndorfer, … A. Ciulli·bioRxiv·Feb 14, 2023
- A simple method for developing lysine targeted covalent protein reagents
R. Gabizon, B. Tivon, … N. London·bioRxiv·Aug 28, 2023
- Non-specificity of Pitstop 2 in clathrin-mediated endocytosis
Anna K Willox, Yasmina M.E. Sahraoui, Stephen J Royle·Biology OpenPeer-reviewed·Apr 4, 2014